



## King's Research Portal

DOI:

[10.1016/j.tim.2017.04.009](https://doi.org/10.1016/j.tim.2017.04.009)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Ho, J., Moyes, D. L., Tavassoli, M., & Naglik, J. R. (2017). The Role of ErbB Receptors in Infection. *Trends in Microbiology*, [29101209]. <https://doi.org/10.1016/j.tim.2017.04.009>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## The role of ErbB receptors in infection

### **Authors:**

Jemima Ho<sup>1\*</sup>, David L. Moyes<sup>2</sup>, Mahvash Tavassoli<sup>3</sup>, Julian R. Naglik<sup>1</sup>

### **Affiliations:**

<sup>1</sup> Mucosal & Salivary Biology Division, Dental Institute, King's College London SE1 1UL, UK

<sup>2</sup> Centre for Host Microbiome interactions, Mucosal & Salivary Biology Division, Dental Institute, King's College London SE1 1UL, UK

<sup>3</sup> Department of Molecular Oncology, Mucosal & Salivary Biology Division, Dental Institute, King's College London SE1 1UL, UK

**\*Correspondence:** jemima.ho@kcl.ac.uk

### **Key words**

# ErbB, EGFR, infection

### **Abstract:**

Members of the epidermal growth factor receptor family (ErbB family) possess a wide distribution and diverse functions ranging from cellular growth to migration and apoptosis. Though highly implicated in a variety of cancers, their involvement in infectious disease is

22 less recognised. A growing body of evidence now highlights the importance of the ErbB  
23 family in a variety of infections. Their role as growth factor receptors, along with other  
24 characteristics, such as surface expression and continuous intracellular trafficking, make this  
25 receptor family ideally placed for exploitation by pathogens. Herein, we review our current  
26 understanding of the role of the ErbB family in the context of infectious disease, exploring  
27 the mechanisms that govern pathogen exploitation of this system.

## 28 **ErbB receptors, a gatekeeper of infectious disease**

29 The co-evolution of host and pathogen has ensured that while the host attempts to  
30 maintain immunological homeostasis, invading organisms look to manipulate host biology  
31 for their own benefit. A central role in this co-evolution is played by host cell receptors  
32 which can both recognise microbes and manipulate cellular responses to them. As such,  
33 pathogens have developed mechanisms to subvert host cell receptors for their own needs;  
34 the ErbB family is one group of host receptors involved in such a relationship.

35

36 The ErbB receptor tyrosine kinase family consists of four members, ErbB1 (epidermal  
37 growth factor receptor, EGFR), ErbB2, ErbB3 and ErbB4, which are expressed on a plethora  
38 of cell types, including epithelial [1], endothelial [2], neuronal and glial [3], bone [4],  
39 adipose [5], liver [6] and cardiovascular cells [7]. Following ligand binding and activation,  
40 oligomerisation of ErbB family members occurs [8]. ErbB signalling is then induced through  
41 phosphorylation of intracellular domains, resulting in the activation of several major  
42 intracellular signalling pathways, including mitogen activated protein (MAP) kinase, nuclear  
43 factor kappa B (NF- $\kappa$ B), phosphoinositide 3 (Pi3) kinase and janus kinase/signal transducer  
44 and activator of transcription (JAK/STAT) pathways. ErbB associated signalling pathways  
45 govern a wide variety of outcomes including cell survival, proliferation, cell death/apoptosis,  
46 angiogenesis, adhesion, differentiation and migration/invasion.

47

48 The majority of studies investigating the role of ErbB receptors in infectious disease focus on  
49 pathogens that primarily infect mucosal surfaces. In this context, ErbB expression on  
50 epithelial cells, the primary point of pathogen contact, plays a crucial role. As membrane  
51 receptors, ErbB functionality and localisation make them well positioned to provide a direct

point of contact and entry into host cells. Not only are ErbB family members regularly endocytosed during their normal life cycle, but pathogen-ErbB ligation [9,10] and ErbB receptor signalling cascades [11–14] can contribute to cellular entry of a diverse range of microbes. Pathogen-mediated hijacking of ErbB signalling pathways also results in prolonged host cell survival [11,12,15–17] as well as altered immune responses [18–26], which may, in turn, enhance pathogen persistence. Crucially, however, their role as growth factor receptors may be required by intracellular organisms, dependent on host cell machinery for self-propagation, such as Hepatitis C virus (HCV) [15,27–29], Epstein Barr virus (EBV) [30] and Human papilloma viruses (HPV) [31]. These pathogens are able to regulate transition through host cell cycle checkpoints and indeed their association with ErbB receptors is linked to cellular transformation and oncogenesis. A direct correlation, however, between regulation of the cell cycle and oncogenesis, has not been shown.

ErbB receptors clearly exhibit a diverse and important range of functions. This review attempts to detail our current understanding of their role of during infection (summarised in Table 1) and contribution towards disease.

#### **ErbB-dependent pathogen entry and invasion:**

Influenza A virus (IAV), respiratory syncytial virus (RSV) and coronaviruses are respiratory pathogens that have been extensively studied in airway epithelial cells with regard to their replication cycle and the host response they elicit. More recently, it has been shown that all three viruses are able to utilise EGFR (ErbB1) for host cell entry. While RSV [32,33] and coronaviruses [34] induce EGFR-dependent macropinocytosis, a non-selective mechanism of internalising large bodies of extracellular material, IAV induces lipid-raft clustering on

surface membranes, resulting in EGFR activation and internalisation of both virus and EGFR [35]. Interestingly, lipid rafts are also important for IAV viral budding and exit from host cells [36–39]. Newly synthesised structural IAV proteins, hemagglutinin (HA) and neuraminidase (NA), can assemble at the cytoplasmic leaflet of lipid rafts [40,41], providing a platform for nascent viral proteins to cluster at, form progeny virus and from which to bud [42]. Given that EGFR localises at lipid rafts [43], a potential role for EGFR during viral exit may also exist (see Outstanding Questions Box). Additionally, the intestinal bacterial pathogen *Campylobacter jejuni* [44] also requires lipid-raft clustering and activation of raft-associated proteins, integrin- $\beta$ 1, EGFR and platelet derived growth factor receptor (PDGFR) for induction of filopodia formation and bacterial invasion.

While such pathogens exploit host internalisation mechanisms, some large microbes appear to have adopted a different mechanism of EGFR-mediated host cell entry, involving manipulation of epithelial junction proteins. The integrity of the epithelium is critical for host defence and is maintained by a variety of proteins located at the interface of adjacent epithelial cells, which include tight junctions, adherens, desmosomes and gap junctions. Such proteins help to maintain intimate contact between neighbouring cells, cellular anchorage and polarity, as well as the paracellular flux of solutes [45–48].

With this in mind, it becomes apparent that targeting such proteins may provide a means of breaching this primary defence barrier, and indeed EGFR has been implicated in modulation of such junction proteins. The bacterial species *Salmonella enterica serovar* Typhimurium is able to activate EGFR and induce expression of Claudin-2, a channel forming tight-junction protein [49] which results in gut epithelium invasion [50]. Claudin-2 activation during

infection is dependent on EGFR phosphorylation, as evidenced by a reduction in bacterial load following siRNA-mediated EGFR downregulation [50]. An alternative mechanism targeting junction proteins for cell entry is utilised by *Staphylococcus aureus*. Cleavage of occludin and E-cadherin, following EGFR activation, facilitates transmigration of *S. aureus* through cell-cell junctions, and inhibition of EGFR activity prevents *S. aureus* migration through an epithelial monolayer [13]. Additionally, *Neisseria gonorrhoeae* induces an EGFR-dependent mechanism of  $\beta$ -catenin redistribution from apical junctions to the cytoplasm, resulting in weakened apical junctions and gonococcal transmigration across the epithelium [51].

Unsurprisingly, enhanced epithelial cell proliferation and improved barrier integrity can provide protective functions against pathogen invasion [52–54], and interestingly both factors can be regulated by ErbB receptors. A protective role of ErbB receptors against infection would be interesting to explore in this context (see Outstanding Questions).

The second ErbB family member, ErbB2, is also targeted by pathogens for cellular entry. *Mycobacterium leprae* directly binds and activates ErbB2 to induce downstream Erk1/Erk2 signalling and bacterial invasion of Schwann cells. Trastuzumab, a potent ErbB2-targeted monoclonal antibody, abrogated both *in vitro* and *in vivo* *M. leprae*-induced myelin damage, highlighting ErbB2 as a crucial factor for leprosy disease [14]. The bacterium *Neisseria meningitidis* also induces recruitment and aggregation of ErbB2, but not other ErbB family members, on endothelial cell membranes, directly beneath sites of bacterial colony formation. Subsequent activation of ErbB2 and downstream Src-dependent signalling led to internalisation of *N. meningitidis* and invasion of target cells [2]. Additionally, the fungus *Candida albicans* utilises both EGFR and ErbB2 to induce endocytosis and invasion into

epithelial cells [55,56]. Reduced severity of oropharangeal candidiasis is observed in mice following treatment with a dual EGFR/ErbB2 kinase inhibitor [55]. Liu et al. also document ErbB2 activation during vulvovaginal candidiasis in humans [57].

Another pathogen-mediated mechanism that promotes host cell entry may involve increased numbers of ErbB receptors at the cell surface. ErbB receptors spend the majority of their life span at the surface of cell membranes but continually undergo internalisation as part of normal processing. The fate of internalised receptors has important consequences for the cell. Potential receptor outcomes following endocytosis, include, recycling back to the surface (associated with proliferation), transport to other cellular compartments such as multivesicular bodies, the nucleus or mitochondria (related to homeostasis), or being targeted for degradation (thought to promote cell death) [58–60]. Pathogens appear to target these trafficking pathways for their own benefit. For example, Hepatitis C virus (HCV) induces the upregulation of host derived Netrin-1, which suppresses EGFR recycling, resulting in enhanced levels of surface EGFR, EGFR activation and subsequent viral endocytosis [27], which occurs via virus-induced EGFR and host-derived CD81 protein binding [28]. Additionally, the ErbB ligand neuregulin-1 has been implicated in enhancing EGFR and ErbB2 surface expression during HCV infection [29]. *N. gonorrhoeae*-induced upregulation of several ErbB ligands was also found to coincide with translocation of both EGFR and ErbB2 receptors to apical surfaces, following infection. This disruption of normal receptor distribution within polarised epithelial cells led to enhanced bacterial invasion and upregulation of EGFR-ligand mRNA was also observed [61]. Conversely, however, *Escherichia coli*-mediated disruption of endosome recycling leads to reduced surface EGFR, transferrin and  $\beta$ 1-integrin expression [62]. Additional examples of EGFR-dependent



mechanisms of host cell entry include *Chlamydia pneumoniae* Pmp21-mediated recruitment of EGFR [10], and EGFR-dependent formation of HPV type 16 (HPV16), Annexin A2 and S100A10 heterotetramers to facilitate HPV16 infection [31]. Interestingly, malignant tissue from patients with HPV-associated cancers, often poorly express EGFR [63,64]. Further understanding of the connection between HPV and EGFR is required to fully appreciate this relationship.

ErbB-dependent host-directed internalisation and targeting of barrier integrity as well as ErbB trafficking, appear to be commonly used mechanisms of cellular entry by a diverse range of pathogens. The development of such distinct pathogen-specific mechanisms to achieve varied methods of internalisation, all of which utilise EGFR, clearly highlights the importance of these receptors as significant points of entry into host cells.

#### **Prolonged host-cell survival through pathogen-mediated EGFR activation**

ErbB-mediated host cellular entry is not the only function of this receptor family that is of potential benefit to invading organisms. ErbB receptors are potent mediators of cellular growth and survival, and unsurprisingly they have become a commonly exploited target for this purpose also. The association between Human cytomegalovirus (HCMV) and EGFR has been well studied. HCMV employs multiple mechanisms of modulating EGFR signalling for its own propagative benefit, including rapid induction of protein kinase B (PKB, alias Akt) activation, a protein kinase downstream of PI3K with important roles in cell cycle regulation. Cojohari et al. showed that use of MK-2206, a highly selective Akt inhibitor during HCMV infection, results in decreased viability of infected monocytes [11]. While uninfected cells utilise the primary isoform of PI3K (P110 $\delta$ ) for Akt signalling, a switch occurs in HCMV-

infected cells to allow use of the less dominant P110 $\beta$  isoform, resulting in prolonged cell survival past the 48 h cell-fate check point. While cell viability was dependent on P110 $\delta$  activity in uninfected cells, inhibition of this predominant isoform did not cause apoptosis in HCMV-infected cells, which instead succumbed to cell death following P110 $\beta$  inhibition [11]. Furthermore, evidence of EGFR-associated promotion of anti-apoptotic proteins, myeloid leukemia sequence (Mcl-1) and heat shock protein 27 (HSP27) [12], as well as modulation of negative regulators of cell survival, such as phosphatase and tensin homolog (PTEN) and SH2 domain-containing inositol 5-phosphatase 1 (SHIP1) [11] has also been shown. In summary, HCMV appears able to activate EGFR signalling, utilise alternative signalling molecules in this pathway, and manipulate EGFR to selectively prevent cell apoptosis for its own propagative benefit.

Additional mechanisms to modulate the cell cycle via ErbB receptors include HCV-induced cell survival through amphiregulin release (AREG, an EGFR ligand) [15], *Helicobacter pylori* induced cell survival and hyperproliferation via EGFR activation [16] and also *Shigella flexneri* promotion of host cell survival through use of phosphatidylinositol 5-phosphate (PI5P), to impair lysosomal degradation and regulation of EGFR trafficking, as well as downstream signalling [17].

Mechanisms of increasing host infected cell survival appear to involve enhanced 'growth' stimulants while suppressing cell death mechanisms. The observation that HCMV, HCV, *H. pylori* and *S. flexneri* are all capable of invading and surviving within host cells suggests that their ability to prolong host cell survival is a specific and evolutionary targeted effect, induced for pathogen benefit.

196

197 **Pathogen induced modulation of immune responses via EGFR:**

198 The ability of pathogens to modulate host immune responses has been long established.

199 However, the importance of ErbB receptors in this context is less known. A number of

200 pathogens have been found to manipulate EGFR to promote immune evasion. IAV and

201 Rhinovirus (RV)-16 are both capable of inhibiting interferon (IFN)- $\lambda$  production, a critical

202 antiviral cytokine of the airways, through an EGFR-dependent mechanism that results in

203 enhanced viral titres [18]. Suppression of CXCL10 (IFN- $\gamma$  induced protein 10 (IP-10)), a

204 monocyte and T cell chemokine, has also been shown following IAV, RV or RSV infection,

205 through virus-induced EGFR signalling [19]. Additionally, NF- $\kappa$ B, a primary transcription206 factor governing immune responses, is targeted during *Klebsiella pneumoniae* infection of

207 bronchial epithelial cells [65]. Here, the EGFR/Pi3K/Erk signalling pathway is activated to

208 result in diminished nuclear translocation of NF- $\kappa$ B [66], likely resulting in the suppressed209 activation of NF- $\kappa$ B and inflammatory responses observed during *K. pneumoniae* infection

210 [65].

211

212 EGFR activation may also be involved in airway remodelling, which is a hallmark feature of

213 chronic obstructive pulmonary disease (COPD) and asthma. Airway remodelling refers to the

214 structural modifications of the airway tissue and can involve increased smooth muscle mass,

215 sub-epithelial fibrosis and mucous gland hyperplasia which contribute to airflow obstruction

216 and impairment of lung function. In a model of epithelial cell infection, stimulation with

217 synthetic double stranded RNA (poly : IC) led to induction of EGFR- and downstream

218 ERK/p38 MAPK- dependent mucin (MUC)-5AC, transforming growth factor (TGF)- $\beta$ 1, matrix

219 metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) cytokine

expression, all of which contribute to airway remodelling [21]. *Pseudomonas aeruginosa* [25] and poly(I:C)-mediated [26] activation of EGFR, also enhanced MUC5AC and subsequent mucus hypersecretion, which contributed to airway mucus obstruction during respiratory disease [25,26].

Retention of MHC-I molecules at the Golgi, by the bacterium *Brucella abortus* is another example of immune evasion via ErbB receptors and results in inhibited MHC-I surface expression [22,67]. Inhibition of EGFR, ErbB2 or the ErbB ligand sheddase protein, tumour necrosis factor- $\alpha$ -converting enzyme (TACE/ADAM17), was each able to modestly recover MHC-I surface expression, whilst Erk1/2 inhibition led to significant restoration of MHC-I surface expression [22]. Furthermore, exposure of the monocyte/macrophage cell-line THP-1, to exogenous EGF, TGF- $\alpha$  or a combination of the two EGFR ligands, was able to mimic *B. abortus*-induced retention of MHC-I at the Golgi and reduced surface MHC-I expression.

Interestingly, Hepatitis B virus (HBV) can promote immune evasion by inducing tolerance. Surface EGFR is upregulated on HBV infected intrahepatic regulatory T cells (Treg), which enhances their immunosuppressive capacity [68]. HBV-infected mice exhibited increased numbers of Treg cells that expressed immunosuppressive cytokines such as interleukin (IL)-10 and TGF- $\beta$ , in addition to an enhanced ability to prevent CD8<sup>+</sup> T cell proliferation, a requirement for HBV clearance [68]. HCMV induced latency is another interesting tactic providing immune evasion and also governed by EGFR activity. During infection, ability to induce latency-associated *UL138*, while suppressing *IE1/IE2* lytic genes, was shown to be EGFR dependent, by use of EGFR specific inhibitors [69]. Additionally, *Mycobacterium tuberculosis* can utilise EGFR-induced p38/MAPK signalling pathways within macrophages,

to prevent proper anti-microbial macrophage responses, resulting in enhanced murine infection [70]. However, in contrast to these pathogen-driven functions of EGFR that contribute to infection, some EGFR-induced host protective functions have also been observed. One study highlights the requirement of EGFR in macrophage activation and function against *H. pylori* bacteria, where EGFR-deficient macrophages exhibited impaired T helper (Th)1 and Th17 adaptive responses, resulting in suppressed *H. pylori*-induced chronic inflammation and disease progression in mice [71]. Additionally, EGFR-dependent *S. aureus*-induced IL-1 $\alpha$  and IL-1 $\beta$  [23], as well as *E. coli*- [24] and virus induced [72–74] IL-8, may be examples of host-beneficial EGFR-dependent responses induced by pathogens.

Together, these studies highlight a complexity of EGFR functionality, which has ability to both contribute to and protect against infections. Mechanisms for immune modulation are highly diverse and pathogen-specific, perhaps emphasising the strength of our intricate immune system and the specialisms of each microbial species. The observation that pathogens are able to augment cellular immune responses through EGFR signalling, again highlights the importance of this class of receptors during infection.

### **ErbB associated cancers**

ErbB receptor activity is highly associated with oncogenic transformation. Several cancers, including head and neck squamous cell carcinoma (HNSCC), lung and colon cancers, are known to result from aberrant ErbB expression or signalling. Aberrations leading to overexpressed or constitutively active ErbB receptors [75–77], overproduced ErbB receptor ligands [15,78–83] and sheddases that cleave ErbB precursor ligands into their mature forms [84–87], have all been shown to cause cellular transformation. Thus, it is perhaps

unsurprising that several cancer-inducing pathogens have been found to promote ErbB activation, with evidence of cellular transformation being directly caused by pathogen induced ErbB signalling. In fact, the ErbB signalling pathway has been implicated in a number of major oncogenic virus infections.

For example, HBV has been shown to induce upregulated expression of EGFR gene and protein, both of which are strongly associated with hepatocellular transformation [88,89]. This virus is also thought to enhance ErbB2 mRNA stability through the HBV-encoded X-protein (HBx), which is itself strongly associated with hepatocellular carcinoma (HCC), resulting in enhanced HCC cell migration [90]. Likewise, HCV infection results in enhanced surface EGFR expression [29,61], EGFR activation and consequent viral entry [28], whilst patients exhibiting certain EGFR polymorphisms spontaneously clear HCV infection [91]. HCV induced AREG overexpression in human hepatoma cells, contributes to prolonged infected-cell survival, cirrhosis and HCC progression [15]. Furthermore, EGFR, which can also be cleaved from apoptotic cells to shut down signalling [92], is found in significantly higher concentrations in HCC patient plasma, in the presence of HCV and HBV infection [93]. Whether this reflects host attempts to curtail aberrant cell proliferation, or is merely a by-product of virus induced apoptosis, remains unclear. So consistent is the increase in soluble EGFR during virus-induced HCC, that it may serve as a marker for such disease [93].

HPV is another virus which has been associated with both EGFR and oncogenesis. Interestingly, in this case, EGFR expression is commonly low [63,64] and has been an area of detailed investigation. One explanation for the existence of 'HPV-positive EGFR-negative' malignancies could lie in the functional redundancy between ErbB receptors as well as an

ability of family members to regulate expression of each other. Indeed, several studies have highlighted an over-expression of ErbB2 and ErbB3 receptors, or even ErbB3 dependency [94], in HPV-positive cancers [95–97], whilst Stindt et al. showed that HCV induced downregulation of ErbB3, upregulates EGFR and ErbB2 expression on hepatocytes [29]. These results were reproducible following suppression of ErbB3 with siRNAs and suggests that ErbB3 can function to impact on the expression of EGFR and ErbB2 [29]. However, the presence of ‘HPV-positive EGFR-positive’ malignancies has also been observed [98,99]. Together, these examples highlight an association between HPV-induced cancer and ErbB receptors, though the full extent of receptor contribution to such disease remains incompletely understood.

Other oncogenic viruses found to have association with EGFR include Epstein Barr Virus (EBV), whose virus-encoded LMP1 protein induces EGFR expression [30], Kaposi’s Sarcoma-associated Herpesvirus (KSHV), which promotes EGFR activation [100] and human T cell leukaemia virus (HTLV), shown to directly induce EGFR-dependent cellular transformation [101].

Additionally, bacteria-induced EGFR-dependent oncogenesis has been documented. The association between *H. pylori* and gastric cancer is highly acknowledged, with studies suggesting that this pathogen remains the strongest known risk factor for stomach tumorigenesis. Early clearance of infection significantly lowers the risk of malignancies [102], which supports its role as a carcinogen and crucially, *H. pylori* infections are strongly linked to the dysregulation of EGFR ligands and/or transactivation of EGFR (reviewed in [103]). The ability of *H. pylori* to dephosphorylate EGFR, is particularly interesting. Pathogen

induced inactivation of EGFR involves activation of host SHP2 tyrosine phosphatase, to result in suppression of the antimicrobial peptide, human beta-defensin 3 (hBD3) expression, to which *H. pylori* is highly susceptible, and sustained bacterial infection [104].

It is curious to note that the ErbB-dependent oncogenic pathogens mentioned herein are capable of replicating intracellularly. Coupled with their ability to induce hyperproliferation, it would be interesting to investigate the role of host cell turnover in ErbB-dependent pathogen survival. Several viruses (HBV, HCV, EBV and HPV among others) are known to require host machinery for protein synthesis and subsequent viral replication; these host translational apparatus can be found in greater abundance at specific points during host cell cycle [105]. As such, subversion of the cell cycle is a common theme where both cycle arrest and induction may occur [106], however the effect of either on associated disease remains unclear. Indeed, not all viruses possessing the ability to regulate the cell cycle, such as IAV and SARS viruses, are particularly associated with oncogenesis. Further investigation into the precise requirements of oncogenic pathogens, leading to host cell survival and replication, and the role of ErbB receptors in this context, may provide valuable insights to developing more effective cancer therapies.

### **Concluding remarks and future perspectives**

There exists a growing body of evidence to support the role of the ErbB receptor family as a critical regulator of pathogen invasion and propagation within the human host. Numerous studies have highlighted pathogen-selective exploitation of ErbB receptors as a mechanism that contributes to host cell entry, cell survival, augmentation of host immunity and cancer (Fig 1, Key Figure). Their cellular localisation, regulated mode of internalised recycling and



functional capacity, make the ErbB family an excellent target for pathogens that require access into host cells in order to self-replicate. Several ErbB-dependent pathogens show capacity to regulate the cell cycle to access host machinery, however the direct effects of this on prolonging host cell survival or enhancing proliferation remain undefined. Malignancies do not occur as a result of all infections and suggests there are likely other factors involved in driving cellular transformation during infection.

On a grander scale, the role of host ErbB receptors during infection is an overlooked aspect of disease which warrants deeper consideration. To date, research in this context has focused predominantly on viral pathogens, with much less detail known regarding bacterial and fungal infections. Investigations are also skewed toward the more prominent EGFR and interest in this host receptor may be warranted as it is the only ErbB member to undergo ligand-induced internalisation, greatly enhancing its appeal for pathogen exploitation. However, given the functional redundancy of ErbB receptors and their potential to regulate expression of each other [29], it would be remiss not to fully investigate the role of all family members. With drug resistance increasing in a plethora of pathogens, there is an immediate and critical need for the development of innovative therapies that target novel factors. As such, ErbB receptors and associated signalling pathways may possess potential value as novel therapeutic targets during pathogenic infection. This notion is supported by a recent study which validates the efficacy of the specific EGFR inhibitor Erlotinib, in conjunction with a broad spectrum tyrosine kinase inhibitor Sunitinib, against a range of evolutionary distinct viral pathogens [107]. Both drugs have FDA approval as immunomodulatory cancer therapies and would also be exciting prospects as novel anti-microbial drugs. However, toxicity concerns that include adverse skin conditions, diarrhoea

364 and heart failure may warrant limitation of their use to treatment of more serious  
365 infections.

366

367 The future of both research and therapies surrounding ErbB receptors is continually  
368 expanding and the next decade should reveal some intriguing and critical information  
369 regarding the interaction between microbes and these receptors.

- 370    1    Tao, R.-H. and Maruyama, I.N. (2008) All EGF(ErbB) receptors have preformed homo-  
371            and heterodimeric structures in living cells. *J. Cell Sci.* 121,
- 372    2    Hoffmann, I. *et al.* (2001) Activation of ErbB2 receptor tyrosine kinase supports  
373            invasion of endothelial cells by *Neisseria meningitidis*. *J. Cell Biol.* 155,
- 374    3    Torp, S.H. *et al.* (1991) Epidermal growth factor receptor expression in human  
375            gliomas. *Cancer Immunol. Immunother.* 33, 61–4
- 376    4    Oda, Y. *et al.* (1995) Expression of growth factors and their receptors in human  
377            osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-  
378            derived growth factor and their receptors: its correlation with proliferating activities  
379            and p53 expression. *Gen. Diagn. Pathol.* 141, 97–103
- 380    5    Donnenberg, A.D. *et al.* (2015) The cell-surface proteome of cultured adipose stromal  
381            cells. *Cytom. Part A* 87, 665–674
- 382    6    Scheving, L.A. *et al.* (2015) Loss of hepatocyte ERBB3 but not EGFR impairs  
383            hepatocarcinogenesis. *Am. J. Physiol. - Gastrointest. Liver Physiol.* 309,
- 384    7    Brea, M.S. *et al.* (2016) Epidermal Growth Factor Receptor Silencing Blunts the Slow  
385            Force Response to Myocardial Stretch. *J. Am. Heart Assoc.* 5,
- 386    8    Needham, S.R. *et al.* (2016) EGFR oligomerization organizes kinase-active dimers into  
387            competent signalling platforms. *Nat. Commun.* 7, 13307
- 388    9    Wang, X. *et al.* (2003) Epidermal growth factor receptor is a cellular receptor for  
389            human cytomegalovirus. *Nature* 424, 456–461
- 390    10    Mölleken, K. *et al.* (2013) The *Chlamydia pneumoniae* invasin protein Pmp21 recruits  
391            the EGF receptor for host cell entry. *PLoS Pathog.* 9, e1003325

- 392 11 Cojohari, O. *et al.* (2016) Human Cytomegalovirus Induces an Atypical Activation of  
393 Akt To Stimulate the Survival of Short-Lived Monocytes. *J. Virol.* 90, 6443–52
- 394 12 Peppenelli, M.A. *et al.* (2016) Human Cytomegalovirus Stimulates the Synthesis of  
395 Select Akt-Dependent Antiapoptotic Proteins during Viral Entry To Promote Survival  
396 of Infected Monocytes. *J. Virol.* 90, 3138–47
- 397 13 Soong, G. *et al.* (2011) Staphylococcus aureus protein A mediates invasion across  
398 airway epithelial cells through activation of RhoA GTPase signaling and proteolytic  
399 activity. *J. Biol. Chem.* 286, 35891–8
- 400 14 Tapinos, N. *et al.* (2006) ErbB2 receptor tyrosine kinase signaling mediates early  
401 demyelination induced by leprosy bacilli. *Nat. Med.* 12, 961–966
- 402 15 Pei, R. *et al.* (2011) Hepatitis C virus infection induces the expression of amphiregulin,  
403 a factor related to the activation of cellular survival pathways and required for  
404 efficient viral assembly. *J. Gen. Virol.* 92, 2237–48
- 405 16 Himaya, S.W.A. *et al.* (2013) EGFR tyrosine kinase inhibitory peptide attenuates  
406 Helicobacter pylori-mediated hyper-proliferation in AGS enteric epithelial cells.  
407 *Toxicol. Appl. Pharmacol.* 269, 205–14
- 408 17 Ramel, D. *et al.* (2011) Shigella flexneri infection generates the lipid PI5P to alter  
409 endocytosis and prevent termination of EGFR signaling. *Sci. Signal.* 4, ra61
- 410 18 Ueki, I.F. *et al.* (2013) Respiratory virus-induced EGFR activation suppresses IRF1-  
411 dependent interferon  $\lambda$  and antiviral defense in airway epithelium. *J. Exp. Med.* 210,  
412 1929–36
- 413 19 Kalinowski, A. *et al.* (2014) EGFR activation suppresses respiratory virus-induced IRF1-

- 414 dependent CXCL10 production. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* 307,
- 415 20 Koff, J.L. *et al.* (2008) Multiple TLRs activate EGFR via a signaling cascade to produce
- 416 innate immune responses in airway epithelium. *Am. J. Physiol. Lung Cell. Mol. Physiol.*
- 417 294, L1068-75
- 418 21 Jiang, J. *et al.* (2016) Regulation of Viral Infection-induced Airway Remodeling
- 419 Cytokine Production by the TLR3-EGFR Signaling Pathway in Human Bronchial
- 420 Epithelial Cells. *COPD* DOI: 10.3109/15412555.2016.1168391
- 421 22 Velásquez, L.N. *et al.* (2016) Inhibition of MHC-I by *Brucella abortus* is an early event
- 422 during infection and involves EGFR pathway. *Immunol. Cell Biol.* DOI:
- 423 10.1038/icb.2016.111
- 424 23 Simanski, M. *et al.* (2016) The Inflammasome and the Epidermal Growth Factor
- 425 Receptor (EGFR) Are Involved in the *Staphylococcus aureus*-Mediated Induction of IL-
- 426 1alpha and IL-1beta in Human Keratinocytes. *PLoS One* 11, e0147118
- 427 24 Fraser-Pitt, D.J. *et al.* (2011) Phosphorylation of the epidermal growth factor receptor
- 428 (EGFR) is essential for interleukin-8 release from intestinal epithelial cells in response
- 429 to challenge with *Escherichia coli* O157 : H7 flagellin. *Microbiology* 157, 2339–2347
- 430 25 Yu, H. *et al.* (2012) Flagellin/TLR5 responses induce mucus hypersecretion by
- 431 activating EGFR via an epithelial cell signaling cascades. *Exp. Cell Res.* 318, 723–31
- 432 26 Shishikura, Y. *et al.* (2016) Extracellular ATP is involved in dsRNA-induced MUC5AC
- 433 production via P2Y2R in human airway epithelium. *Respir. Res.* 17, 121
- 434 27 Plissonnier, M.-L. *et al.* (2016) Epidermal Growth Factor Receptor-Dependent Mutual
- 435 Amplification between Netrin-1 and the Hepatitis C Virus. *PLoS Biol.* 14, e1002421

- 436 28 Diao, J. *et al.* (2012) Hepatitis C virus induces epidermal growth factor receptor  
437 activation via CD81 binding for viral internalization and entry. *J. Virol.* 86, 10935–49
- 438 29 Stindt, S. *et al.* (2016) Hepatitis C Virus Activates a Neuregulin-Driven Circuit to  
439 Modify Surface Expression of Growth Factor Receptors of the ErbB Family. *PLoS One*  
440 11, e0148711
- 441 30 Miller, W.E. *et al.* (1995) The Epstein-Barr virus latent membrane protein 1 induces  
442 expression of the epidermal growth factor receptor. *J. Virol.* 69, 4390–8
- 443 31 Dziduszko, A. and Ozbun, M.A. (2013) Annexin A2 and S100A10 regulate human  
444 papillomavirus type 16 entry and intracellular trafficking in human keratinocytes. *J.*  
445 *Virol.* 87, 7502–15
- 446 32 Currier, M.G. *et al.* (2016) EGFR Interacts with the Fusion Protein of Respiratory  
447 Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression. *PLoS*  
448 *Pathog.* 12, e1005622
- 449 33 Krzyzaniak, M.A. *et al.* (2013) Host cell entry of respiratory syncytial virus involves  
450 macropinocytosis followed by proteolytic activation of the F protein. *PLoS Pathog.* 9,  
451 e1003309
- 452 34 Freeman, M.C. *et al.* (2014) Coronaviruses induce entry-independent, continuous  
453 macropinocytosis. *MBio* 5, e01340-14
- 454 35 Eierhoff, T. *et al.* (2010) The Epidermal Growth Factor Receptor (EGFR) Promotes  
455 Uptake of Influenza A Viruses (IAV) into Host Cells. *PLoS Pathog.* 6, e1001099
- 456 36 Mariani, C. *et al.* (2014) Role of Gag and lipids during HIV-1 assembly in CD4(+) T cells  
457 and macrophages. *Front. Microbiol.* 5, 312

- 458 37 Licata, J.M. *et al.* (2003) Overlapping motifs (PTAP and PPEY) within the Ebola virus  
459 VP40 protein function independently as late budding domains: involvement of host  
460 proteins TSG101 and VPS-4. *J. Virol.* 77, 1812–9
- 461 38 Marty, A. *et al.* (2004) Association of matrix protein of respiratory syncytial virus with  
462 the host cell membrane of infected cells. *Arch. Virol.* 149, 199–210
- 463 39 Nguyen, D.H. and Hildreth, J.E. (2000) Evidence for budding of human  
464 immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid  
465 rafts. *J. Virol.* 74, 3264–72
- 466 40 Ohkura, T. *et al.* (2014) Influenza A virus hemagglutinin and neuraminidase mutually  
467 accelerate their apical targeting through clustering of lipid rafts. *J. Virol.* 88, 10039–55
- 468 41 Takeda, M. *et al.* (2003) Influenza virus hemagglutinin concentrates in lipid raft  
469 microdomains for efficient viral fusion. *Proc. Natl. Acad. Sci. U. S. A.* 100, 14610–7
- 470 42 Takeda, M. (2004) [Lipid raft and influenza virus--viral glycoproteins on a raft]. *Uirusu*  
471 54, 9–15
- 472 43 Schlessinger, J. (2002) Ligand-Induced, Receptor-Mediated Dimerization and  
473 Activation of EGF Receptor. *Cell* 110, 669–672
- 474 44 Krause-Gruszczynska, M. *et al.* (2011) The signaling pathway of *Campylobacter jejuni*-  
475 induced Cdc42 activation: Role of fibronectin, integrin beta1, tyrosine kinases and  
476 guanine exchange factor Vav2. *Cell Commun. Signal.* 9, 32
- 477 45 Guichard, A. *et al.* (2014) RAB11-mediated trafficking in host–pathogen interactions.  
478 *Nat. Rev. Microbiol.* 12, 624–634
- 479 46 Hammad, H. and Lambrecht, B.N. (2015) Barrier Epithelial Cells and the Control of

- 480 Type 2 Immunity. *Immunity* 43, 29–40
- 481 47 Lu, R.-Y. *et al.* (2014) The role of epithelial tight junctions involved in pathogen  
482 infections. *Mol. Biol. Rep.* 41, 6591–6610
- 483 48 Zihni, C. *et al.* (2014) Signalling at tight junctions during epithelial differentiation and  
484 microbial pathogenesis. *J. Cell Sci.* 127, 3401–3413
- 485 49 R. Rosenthal, S. Milatz, S. Krug, B. Oelrich, J. D. Schulzke, S. Amasheh, D. Gunzel, M.F.  
486 (2010) Claudin-2, a component of the tight junction, forms a paracellular water  
487 channel. *J. Cell Sci.* 123, 1913–1921
- 488 50 Zhang, Y. *et al.* (2013) Salmonella infection upregulates the leaky protein claudin-2 in  
489 intestinal epithelial cells. *PLoS One* 8, e58606
- 490 51 Edwards, V.L. *et al.* (2013) *Neisseria gonorrhoeae* breaches the apical junction of  
491 polarized epithelial cells for transmigration by activating EGFR. *Cell. Microbiol.* 15,  
492 1042–1057
- 493 52 Hu, G.-Q. *et al.* (2016) AIM2 contributes to the maintenance of intestinal integrity via  
494 Akt and protects against Salmonella mucosal infection. *Mucosal Immunol.* 9, 1330–  
495 1339
- 496 53 Sim, S. and Hibberd, M.L. (2016) *Caenorhabditis elegans* susceptibility to gut  
497 *Enterococcus faecalis* infection is associated with fat metabolism and epithelial  
498 junction integrity. *BMC Microbiol.* 16, 6
- 499 54 Burgener, A. *et al.* (2015) HIV and mucosal barrier interactions: consequences for  
500 transmission and pathogenesis. *Curr. Opin. Immunol.* 36, 22–30
- 501 55 Solis, N. V. *et al.* (2017) The Aryl Hydrocarbon Receptor Governs Epithelial Cell



- 502 Invasion during Oropharyngeal Candidiasis. *MBio* 8, e00025-17
- 503 56 Zhu, W. *et al.* (2012) EGFR and HER2 receptor kinase signaling mediate epithelial cell  
504 invasion by *Candida albicans* during oropharyngeal infection. *Proc. Natl. Acad. Sci. U.*  
505 *S. A.* 109, 14194–9
- 506 57 Liu, Y. *et al.* (2015) New signaling pathways govern the host response to *C. albicans*  
507 infection in various niches. *Genome Res.* 25, 679–89
- 508 58 Tomas, A. *et al.* (2014) EGF receptor trafficking: consequences for signaling and  
509 cancer. *Trends Cell Biol.* 24, 26–34
- 510 59 Wiley, H.S. (2003) Trafficking of the ErbB receptors and its influence on signaling. *Exp.*  
511 *Cell Res.* 284, 78–88
- 512 60 Wang, Y.-N. *et al.* (2012) Nuclear functions and subcellular trafficking mechanisms of  
513 the epidermal growth factor receptor family. *Cell Biosci.* 2, 13
- 514 61 Swanson, K. V. *et al.* (2011) *Neisseria gonorrhoeae*-induced transactivation of EGFR  
515 enhances gonococcal invasion. *Cell. Microbiol.* 13, 1078–1090
- 516 62 Clements, A. *et al.* (2014) Enterohaemorrhagic *Escherichia coli* inhibits recycling  
517 endosome function and trafficking of surface receptors. *Cell. Microbiol.* 16, 1693–705
- 518 63 Almadori, G. *et al.* (2001) Human Papillomavirus Infection and Epidermal Growth  
519 Factor Receptor Expression in Primary Laryngeal Squamous Cell Carcinoma. *Clin.*  
520 *Cancer Res.* 7,
- 521 64 Yu, J.J. *et al.* (2010) HPV infection and EGFR activation/alteration in HIV-infected East  
522 African patients with conjunctival carcinoma. *PLoS One* 5, e10477
- 523 65 Regueiro, V. *et al.* (2011) *Klebsiella pneumoniae* subverts the activation of

- 524 inflammatory responses in a NOD1-dependent manner. *Cell. Microbiol.* 13, 135–153
- 525 66 Frank, C.G. *et al.* (2013) *Klebsiella pneumoniae* targets an EGF receptor-dependent  
526 pathway to subvert inflammation. *Cell. Microbiol.* 15, 1212–1233
- 527 67 Barrionuevo, P. *et al.* (2013) *Brucella abortus* induces intracellular retention of MHC-I  
528 molecules in human macrophages down-modulating cytotoxic CD8<sup>+</sup> T cell responses.  
529 *Cell. Microbiol.* 15, 487–502
- 530 68 Dai, K. *et al.* (2014) Amphiregulin promotes the immunosuppressive activity of  
531 intrahepatic CD4<sup>+</sup> regulatory T cells to impair CD8<sup>+</sup> T cell immunity against hepatitis  
532 B virus infection. *Immunology* 144, n/a-n/a
- 533 69 Kim, J.H. *et al.* (2017) Human Cytomegalovirus Requires Epidermal Growth Factor  
534 Receptor Signaling To Enter and Initiate the Early Steps in the Establishment of  
535 Latency in CD34(+) Human Progenitor Cells. *J. Virol.* 91, e01206-16
- 536 70 Stanley, S.A. *et al.* (2014) Identification of Host-Targeted Small Molecules That  
537 Restrict Intracellular Mycobacterium tuberculosis Growth. *PLoS Pathog.* 10, e1003946
- 538 71 Hardbower, D.M. *et al.* (2016) EGFR regulates macrophage activation and function in  
539 bacterial infection. *J. Clin. Invest.* 126, 3296–3312
- 540 72 Ito, Y. *et al.* (2015) Influenza induces IL-8 and GM-CSF secretion by human alveolar  
541 epithelial cells through HGF/c-Met and TGF- $\alpha$ /EGFR signaling. *Am. J. Physiol. - Lung*  
542 *Cell. Mol. Physiol.* 308,
- 543 73 Monick, M.M. *et al.* (2005) Activation of the epidermal growth factor receptor by  
544 respiratory syncytial virus results in increased inflammation and delayed apoptosis. *J.*  
545 *Biol. Chem.* 280, 2147–58

- 546 74 Liu, K. *et al.* (2008) Epidermal growth factor receptor signaling to Erk1/2 and STATs  
547 control the intensity of the epithelial inflammatory responses to rhinovirus infection.  
548 *J. Biol. Chem.* 283, 9977–85
- 549 75 Shigematsu, H. *et al.* (2005) Clinical and biological features associated with epidermal  
550 growth factor receptor gene mutations in lung cancers. *J. Natl. Cancer Inst.* 97, 339–  
551 46
- 552 76 Lynch, T.J. *et al.* (2004) Activating Mutations in the Epidermal Growth Factor Receptor  
553 Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. *N. Engl. J.*  
554 *Med.* 350, 2129–2139
- 555 77 Okabe, T. *et al.* (2007) Differential Constitutive Activation of the Epidermal Growth  
556 Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation  
557 and Amplification. *Cancer Res.* 67,
- 558 78 Kuramochi, H. *et al.* (2012) Amphiregulin and Epiregulin mRNA expression in primary  
559 colorectal cancer and corresponding liver metastases. *BMC Cancer* 12, 88
- 560 79 Neufert, C. *et al.* (2013) Tumor fibroblast–derived epiregulin promotes growth of  
561 colitis-associated neoplasms through ERK. *J. Clin. Invest.* 123, 1428–1443
- 562 80 Khambata-Ford, S. *et al.* (2007) Expression of Epiregulin and Amphiregulin and K-ras  
563 Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients  
564 Treated With Cetuximab. *J. Clin. Oncol.* 25, 3230–3237
- 565 81 Harada, K. *et al.* (1999) Transforming growth factor- $\beta$  and epidermal growth factor  
566 receptor in chronic liver disease and hepatocellular carcinoma. *Liver Int.* 19, 318–325
- 567 82 Qiao, Q. *et al.* Over expression of transforming growth factor- $\alpha$  and epidermal

- 568 growth factor receptor in human hepatic cirrhosis tissues. *Hepatogastroenterology*.  
 569 55, 169–72
- 570 83 Inui, Y. *et al.* (1994) Expression of heparin-binding epidermal growth factor in human  
 571 hepatocellular carcinoma. *Gastroenterology* 107, 1799–804
- 572 84 Nakagawa, M. *et al.* (2009) Up-regulated expression of ADAM17 in gastrointestinal  
 573 stromal tumors: coexpression with EGFR and EGFR ligands. *Cancer Sci.* 100, 654–662
- 574 85 Mullooly, M. *et al.* (2015) ADAM10: a new player in breast cancer progression? *Br. J.*  
 575 *Cancer* 113, 945–951
- 576 86 Sung, S.-Y. *et al.* (2006) Oxidative Stress Induces ADAM9 Protein Expression in Human  
 577 Prostate Cancer Cells. *Cancer Res.* 66,
- 578 87 Ohtsuka, T. *et al.* (2006) ADAM28 is overexpressed in human non-small cell lung  
 579 carcinomas and correlates with cell proliferation and lymph node metastasis. *Int. J.*  
 580 *Cancer* 118, 263–273
- 581 88 Menzo, S. *et al.* (1993) Trans-activation of epidermal growth factor receptor gene by  
 582 the hepatitis B virus X-gene product. *Virology* 196, 878–82
- 583 89 Miyaki, M. *et al.* (2000) Malignant transformation and EGFR activation of  
 584 immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human  
 585 hepatocellular carcinoma. *Int. J. cancer* 85, 518–22
- 586 90 Hung, C.-M. *et al.* (2014) Hepatitis B Virus X Upregulates HuR Protein Level to Stabilize  
 587 HER2 Expression in Hepatocellular Carcinoma Cells. *Biomed Res. Int.* 2014, 1–9
- 588 91 Carapito, R. *et al.* (2015) Polymorphisms in EGFR and IL28B are associated with  
 589 spontaneous clearance in an HCV-infected Iranian population. *Genes Immun.* 16, 514–

590 518

591 92 He, Y.-Y. *et al.* (2006) Cleavage of epidermal growth factor receptor by caspase during  
592 apoptosis is independent of its internalization. *Oncogene* 25, 1521–1531

593 93 Divella, R. *et al.* (2012) Circulating Transforming Growth Factor-Beta and Epidermal  
594 Growth Factor Receptor as related to virus infection in liver carcinogenesis.  
595 *Anticancer Res.*

596 94 Brand, T.M. *et al.* (2016) Human papillomavirus regulates HER3 expression in head  
597 and neck cancer: implications for targeted HER3 therapy in HPV(+) patients. *Clin.*  
598 *Cancer Res.* DOI: 10.1158/1078-0432.CCR-16-2203

599 95 Narisawa-Saito, M. *et al.* (2007) HPV16 E6-mediated stabilization of ErbB2 in  
600 neoplastic transformation of human cervical keratinocytes. *Oncogene* 26, 2988–2996

601 96 Pollock, N.I. *et al.* (2015) Increased Expression of HER2, HER3, and HER2:HER3  
602 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay:  
603 Implications for Targeted Therapies. *Clin. Cancer Res.* 21,

604 97 Stankiewicz, E. *et al.* (2011) Alternative HER/PTEN/Akt Pathway Activation in HPV  
605 Positive and Negative Penile Carcinomas. *PLoS One* 6, e17517

606 98 Reimers, N. *et al.* (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to  
607 predict prognosis in oropharyngeal cancer. *Int. J. Cancer* 120, 1731–1738

608 99 Kong, C.S. *et al.* (2009) The Relationship Between Human Papillomavirus Status and  
609 Other Molecular Prognostic Markers in Head and Neck Squamous Cell Carcinomas.  
610 *Int. J. Radiat. Oncol.* 74, 553–561

611 100 Cheng, F. *et al.* (2015) Screening of the Human Kinome Identifies MSK1/2-CREB1 as an


- 612 Essential Pathway Mediating Kaposi's Sarcoma-Associated Herpesvirus Lytic  
 613 Replication during Primary Infection. *J. Virol.* 89, 9262–80
- 614 101 Chen, L. *et al.* (2015) Foxp3-dependent transformation of human primary CD4+ T  
 615 lymphocytes by the retroviral protein tax. *Biochem. Biophys. Res. Commun.* 466, 523–  
 616 9
- 617 102 Wong, B.C.-Y. *et al.* (2004) Helicobacter pylori Eradication to Prevent Gastric Cancer in  
 618 a High-Risk Region of China. *JAMA* 291, 187
- 619 103 Polk, D.B. and Peek, R.M. (2010) Helicobacter pylori: gastric cancer and beyond. *Nat.*  
 620 *Rev. Cancer* 10, 403–414
- 621 104 Bauer, B. *et al.* (2012) The Helicobacter pylori virulence effector CagA abrogates  
 622 human  $\beta$ -defensin 3 expression via inactivation of EGFR signaling. *Cell Host Microbe*  
 623 11, 576–86
- 624 105 Walsh, D. *et al.* (2013) Tinkering with translation: protein synthesis in virus-infected  
 625 cells. *Cold Spring Harb. Perspect. Biol.* 5, a012351
- 626 106 Bagga, S. and Bouchard, M.J. (2014) Cell Cycle Regulation During Viral Infection. pp.  
 627 165–227
- 628 107 Bekerman, E. *et al.* (2017) Anticancer kinase inhibitors impair intracellular viral  
 629 trafficking and exert broad-spectrum antiviral effects. *J. Clin. Invest.* DOI:  
 630 10.1172/JCI89857

631

**Key Fig: Primary mechanisms and targets modulated or induced by microbes, involving ErbB receptors.**

Pathogen induced mechanisms of host cell entry can involve (A): ErbB-mediated lipid raft clustering, (B): inhibition of ErbB endocytosis resulting in elevated surface receptor expression, (C): ErbB-mediated macropinocytosis and (D): modulation of junction proteins.

Pathogens can also manipulate factors that govern immune responses through ErbB receptor exploitation. Mechanisms here include (E): altering cytokine expression in infected cells and (F): inhibition of NF- $\kappa$ B nuclear-translocation. Additionally some pathogens that are able to regulate the cell cycle also appear able to induce host cell survival, proliferation or oncogenesis (G).





**Outstanding questions box:**

- The EGFR has been associated with lipid raft clustering and viral entry mechanisms, but lipid raft aggregation is also involved in viral egress. Does EGFR, therefore, play a role during budding of nascent viral progeny?
- Both enhanced cell turnover and barrier integrity have been shown to be protective against pathogen invasion, factors that ErbB receptors are directly capable of inducing. Is there potential to enhance this protective role of ErbB receptors as a preventative measure against infection?
- How efficacious would current ErbB targeted therapies be against pathogen infection in humans? Toxicity and resistance against such drugs has been observed in cancer patients. Are the mechanisms behind such events relevant in the setting of pathogenic infection?
- Is ErbB receptor function capable of directly driving pathogen-induced cellular transformation? If so, at which stage(s) of cancer does this contribute? During initial oncogenesis or maintenance and progression of cancer?

*Table 1: ErbB-dependent microbes and their mechanisms of receptor exploitation*

<b>Virus</b>	<b>Mechanism of ErbB exploitation</b>	<b>Outcomes</b>	<b>Ref.</b>
EBV	Induces of EGFR expression	Host cell proliferation	[30]
HBV	Induces of surface EGFR expression	Host cell proliferation	[88,89]
HCV	Disrupts EGFR recycling to enhance surface expression through host protein Netrin-1	Host cell entry	[27]
	Enhances EGFR and ErbB2 surface expression through NRG-1 dependant mechanism		[29]
	Induces AREG-dependant circumvention of apoptosis; induces proliferation and transformation	Host cell survival and proliferation	[15]
HCMV	Alters EGFR signalling molecules to bypass cell-fate check points and enhance production of cell cycle proteins	Host cell survival	[11,12]
	<a href="#">EGFR activation promotes latency by inducing latent, but suppressing of lytic gene expression</a>	Immune evasion	[69]
HPV	Induces EGFR-dependent translocation of AnxA2 results in formation of the HPV-AnxA2-S100A10 binding complex required for viral entry	Host cell entry	[31]
HTLV	Induces EGFR activation resulting in cellular transformation in CD4 <sup>+</sup> Tcells	Host cell proliferation	[101]
IAV	Induces of lipid raft clustering. Activates EGFR and other RTKs leading to cellular internalisation	Host cell entry	[35]
	Suppresses IFN- $\lambda$ and CXCL10 through EGFR activation	Immune modulation	[18,19]
KSHV	Oncogenic pathogen induces activation of EGFR signalling	Unconfirmed	[100]
RV	Suppresses RV-induced IFN- $\lambda$ and CXCL10 expression via EGFR activation	Immune modulation	[18,19]
RSV	Induces EGFR dependent macropinocytosis	Host cell entry	[32,33]
	Suppresses RSV-induced CXCL10 expression via EGFR activation	Immune modulation	[19]
SARS	Induces EGFR dependent macropinocytosis	Host cell entry	[34]

Table 1 continued:

Bacteria	Mechanism	Outcomes	Ref.
<i>Brucella abortus</i>	Inhibits MHC-I expression potentially involving EGFR, ErbB2 and/or TACE sheddase.	Immune modulation	[22,67]
<i>Campylobacter jejuni</i>	Induces lipid raft clustering and EGFR activation	Host cell entry	[44]
<i>Chlamydia pneumoniae</i>	Bacterial Pmp21 adhesin directly binds EGFR	Host cell entry	[10]
<i>Escherichia coli</i>	Disrupts endosome trafficking resulting in diminished surface EGFR	Unconfirmed	[62]
<i>Helicobacter pylori</i>	Induces EGFR dependent $\beta$ -catenin nuclear translocation and PI3K/Akt signalling	Host cell survival	[16]
	Dephosphorylates EGFR to inhibit hBD3 expression and promote infection	Immune modulation	[104]
<i>Klebsiella pneumoniae</i>	Induces EGFR dependent inhibition of NF- $\kappa$ B translocation	Immune modulation	[65,66]
<i>Neisseria gonorrhoeae</i>	Induces redistribution of $\beta$ -catenin from apical junction to cytoplasm through EGFR activation.	Host cell entry	[51]
	Induces translocation of ErbB2 and ErbB3 to apical surfaces		[61]
<i>Neisseria meningitidis</i>	Recruits and activates ErbB2 receptors	Host cell entry	[2]
<i>Mycobacterium leprae</i>	Directly binds ErbB2 receptors	Host cell entry	[14]
<i>Mycobacterium tuberculosis</i>	Prevent proper macrophage function resulting in enhanced infection	Immune modulation	[70]
<i>Salmonella Typhimurium</i>	Induces Claudin 2 expression through EGFR and downstream JNK activation	Host cell entry	[50]
<i>Shigella flexneri</i>	Induces PI5P production to regulate EGFR trafficking	Host cell survival	[17]
<i>Staphylococcus aureus</i>	Cleaves junction proteins occludin and E-cadherin to facilitate transmigration. EGFR activation is required	Host cell entry	[13]
Fungi	Mechanism	Outcomes	Ref.
<i>Candida albicans</i>	EGFR and ErbB2 dependent endocytosis	Host cell entry	[55,56]

**Trends box:**

- A wide and diverse variety of microbes have each evolved distinct mechanisms to exploit ErbB receptors, highlighting this receptor kinase family as a critical factor in initiation and maintenance of pathogen infections.
- ErbB family members are utilised by pathogens attempting to gain cellular entry, subvert immune responses, and manipulate the cell cycle of infected host cells. These events support and are necessary for pathogen persistence.
- Pathogen-mediated ErbB-exploitation may contribute to cellular transformation and oncogenesis in a variety of cancers.
- The use of existing FDA approved drugs that target ErbB receptors and associated signalling components may offer potential future therapies against infection.